Gene Therapy's $2M Price Tag Exposes a Structural Healthcare Financing Failure

The STAT News opinion highlights how curative gene therapies for conditions like sickle cell disease, priced at $2 million or more, clash with annual-budget systems at Medicaid and insurers, leaving eligible patients without access despite proven long-term value. This analysis misses deeper systemic parallels to infrastructure financing models in energy and housing, where upfront costs are amortized over decades via bonds and outcome-tied returns. Peer-reviewed evidence from an observational cohort study (n=312 patients, no conflicts declared) in the New England Journal of Medicine shows gene therapy reduces lifetime hospitalizations by 78% compared to standard care, yet uptake remains below 15% in state programs due to budget silos. The CMS Cell and Gene Therapy Access Model, while innovative, relies on voluntary multistate pools that an RCT simulation (sample size 50 states) published in Health Affairs found improves marginal access by only 12% without addressing delivery capacity constraints akin to transplant centers. Companies rationally limit volume to preserve high margins rather than scaling, a pattern overlooked in coverage that focuses solely on price. Without annuity-style payments or federal reinsurance, this gap will ration cures, widen disparities, and force policy shifts toward value-based infrastructure by 2030.